| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 16104 | Current Opinion in Biotechnology | 2012 | 8 Pages |
Small molecules produced in Nature possess exquisite chemical diversity and continue to be an inspiration for the development of new therapeutic agents. In their host organisms, natural products are assembled and modified using dedicated biosynthetic pathways. By rationally reprogramming and manipulating these pathways, unnatural metabolites containing enhanced structural features that were otherwise inaccessible can be obtained. Additionally, new chemical entities can be synthesized by developing the enzymes that carry out these complicated chemical reactions into biocatalysts. In this review, we will discuss a variety of combinatorial biosynthetic strategies, their technical challenges, and highlight some recent (since 2007) examples of rationally designed metabolites, as well as platforms that have been established for the production and modification of clinically important pharmaceutical compounds.
Graphical abstractFigure optionsDownload full-size imageDownload high-quality image (148 K)Download as PowerPoint slideHighlights► Reprogramming natural product assembly lines have yielded new compounds. ► Substrate specificity of tailoring enzymes can be exploited to afford derivatives. ► Expression and manipulation of pathways have been performed in surrogate hosts.
